Literature DB >> 10458300

Histopathologic study of presumed parafoveal telangiectasis.

B Eliassi-Rad1, W R Green.   

Abstract

PURPOSE: To report the postmortem histopathologic features that closely resemble the clinical features of parafoveal telangiectasis.
METHODS: Light and electron microscopy.
RESULTS: Histopathologic features included macular edema; telangiectatic vessels; retinal, subretinal, and superficial retinal neovascularization; retinal pigment epithelial hyperplasia around neovascular aggregates; retinal-choroidal vascular anastomosis; and superficial pigmented cells with lipofuscin.
CONCLUSION: The postmortem histopathologic findings in a 36-year-old woman with Down syndrome and other systemic conditions correlate with features noted in previous reports of presumed parafoveal telangiectasis.

Entities:  

Mesh:

Year:  1999        PMID: 10458300     DOI: 10.1097/00006982-199907000-00011

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  15 in total

1.  Treatment of nonneovascular idiopathic macular telangiectasia type 2 with intravitreal ranibizumab: results of a phase II clinical trial.

Authors:  Brian C Toy; Euna Koo; Catherine Cukras; Catherine B Meyerle; Emily Y Chew; Wai T Wong
Journal:  Retina       Date:  2012-05       Impact factor: 4.256

2.  Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia.

Authors:  Buğra Karasu; Betul Onal Gunay
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-11-25       Impact factor: 3.117

3.  Basement membrane changes in capillaries of the ageing human retina.

Authors:  Michael B Powner; Andrew Scott; Meidong Zhu; Peter M G Munro; Alexander J E Foss; Gregory S Hageman; Mark C Gillies; Marcus Fruttiger
Journal:  Br J Ophthalmol       Date:  2011-05-23       Impact factor: 4.638

4.  Perifoveal müller cell depletion in a case of macular telangiectasia type 2.

Authors:  Michael B Powner; Mark C Gillies; Marina Tretiach; Andrew Scott; Robyn H Guymer; Gregory S Hageman; Marcus Fruttiger
Journal:  Ophthalmology       Date:  2010-08-03       Impact factor: 12.079

5.  Demographic features of idiopathic macular telangiectasia in Japanese patients.

Authors:  Ichiro Maruko; Tomohiro Iida; Yukinori Sugano; Akira Ojima; Hiroshi Oyamada; Tetsuju Sekiryu
Journal:  Jpn J Ophthalmol       Date:  2012-01-06       Impact factor: 2.447

6.  Clinicopathological correlation of deep retinal vascular anomalous complex in age related macular degeneration.

Authors:  B A Lafaut; S Aisenbrey; C Vanden Broecke; K U Bartz-Schmidt
Journal:  Br J Ophthalmol       Date:  2000-11       Impact factor: 4.638

7.  The IS/OS junction layer in the natural history of type 2 idiopathic macular telangiectasia.

Authors:  Ferenc B Sallo; Tunde Peto; Catherine Egan; Ute E K Wolf-Schnurrbusch; Traci E Clemons; Mark C Gillies; Daniel Pauleikhoff; Gary S Rubin; Emily Y Chew; Alan C Bird
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-11-29       Impact factor: 4.799

8.  Idiopathic juxtafoveolar retinal telangiectasis: a current review.

Authors:  Sawsan R Nowilaty; Hanan N Al-Shamsi; Wajeeha Al-Khars
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

Review 9.  Macular telangiectasia type 2.

Authors:  Peter Charbel Issa; Mark C Gillies; Emily Y Chew; Alan C Bird; Tjebo F C Heeren; Tunde Peto; Frank G Holz; Hendrik P N Scholl
Journal:  Prog Retin Eye Res       Date:  2012-12-03       Impact factor: 21.198

10.  Comparison of observation, intravitreal bevacizumab, or pars plana vitrectomy for non-proliferative type 2 idiopathic macular telangiectasia.

Authors:  Eric J Sigler; John C Randolph; Jorge I Calzada; Steve Charles
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-09-06       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.